{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:32:34Z","timestamp":1757622754954,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,8]]},"DOI":"10.7759\/cureus.91847","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:14:00Z","timestamp":1757351640000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding the Factors Related to Early Discontinuation of Lutetium-177 Vipivotide Treatment in Men With Metastatic Castration-Resistant Prostate Cancer at a Single Institution"],"prefix":"10.7759","author":[{"given":"Mannat","family":"Bedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danishi","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Whatts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Boggula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aria","family":"Kieft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Dyson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Baran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Whatts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Cancer Institute. SEER Cancer Stat Facts. Prostate cancer. (2024). Accessed. December 4, 2024: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"ref2","unstructured":"National Center for Health Statistics. Centers for Disease Control and Prevention, 2023. Mortality rates by states 2018-2022. (2023). Accessed. December 4, 2024: https:\/\/cancerstatisticscenter.cancer.org\/rates\/mortality."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam SJ","year":"2022","unstructured":"Keam SJ. Lutetium Lu 177 vipivotide tetraxetan: first approval. Mol Diagn Ther. 2022, 26:467-75. 10.1007\/s40291-022-00594-2","journal-title":"Mol Diagn Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091247","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henr\u00edquez I","year":"2021","unstructured":"Henr\u00edquez I, Roach M 3rd, Morgan TM, Bossi A, G\u00f3mez JA, Abuchaibe O, Cou\u00f1ago F. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines. 2021, 9:1247. 10.3390\/biomedicines9091247","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2023.59.1.3476574","article-title":"Lutetium Lu 177 vipivotide tetraxetan for prostate cancer","volume":"59","author":"Liu X","year":"2023","unstructured":"Liu X, Fang GC, Lu H, Shi ZD, Chen ZS, Han CH. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer. Drugs Today (Barc). 2023, 59:37-49. 10.1358\/dot.2023.59.1.3476574","journal-title":"Drugs Today (Barc)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor O","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al.. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021, 385:1091-103. 10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman MS","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al.. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021, 397:P797-804. 10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah J","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, et al.. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023, 29:1651-7. 10.1158\/1078-0432.CCR-22-2875","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2023.09.003","article-title":"Palliative radiotherapy: new prognostic factors for patients with bone metastasis","volume":"28","author":"Steinvoort-Draat IN","year":"2024","unstructured":"Steinvoort-Draat IN, Otto-Vollaard L, Quint S, Tims JL, de Pree IM, Nuyttens JJ. Palliative radiotherapy: new prognostic factors for patients with bone metastasis. Cancer Radiother. 2024, 28:236-41. 10.1016\/j.canrad.2023.09.003","journal-title":"Cancer Radiother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05082-5","article-title":"Prediction of response and survival after standardized treatment with 7400\u00a0MBq (177)Lu-PSMA-617 every 4\u00a0weeks in patients with metastatic castration-resistant prostate cancer","volume":"48","author":"Rasul S","year":"2021","unstructured":"Rasul S, Hartenbach M, Wollenweber T, et al.. Prediction of response and survival after standardized treatment with 7400\u00a0MBq (177)Lu-PSMA-617 every 4\u00a0weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2021, 48:1650-7. 10.1007\/s00259-020-05082-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61370-2","article-title":"Hematological and renal toxicity in mice after three cycles of high activity [(177)Lu]Lu-PSMA-617 with or without human \u03b1(1)-microglobulin","volume":"14","author":"Kristiansson A","year":"2024","unstructured":"Kristiansson A, Vilhelmsson Timmermand O, Altai M, Strand SE, \u00c5kerstr\u00f6m B, \u00d6rbom A. Hematological and renal toxicity in mice after three cycles of high activity [(177)Lu]Lu-PSMA-617 with or without human \u03b1(1)-microglobulin. Sci Rep. 2024, 14:10787. 10.1038\/s41598-024-61370-2","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","article-title":"[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich U","year":"2022","unstructured":"Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022, 15:1292. 10.3390\/ph15101292","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379014-understanding-the-factors-related-to-early-discontinuation-of-lutetium-177-vipivotide-treatment-in-men-with-metastatic-castration-resistant-prostate-cancer-at-a-single-institution","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:14:02Z","timestamp":1757351642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379014-understanding-the-factors-related-to-early-discontinuation-of-lutetium-177-vipivotide-treatment-in-men-with-metastatic-castration-resistant-prostate-cancer-at-a-single-institution"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.91847","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}